Biosceptre is a UK based biotech R&D business investigating and exploiting a promising new target for the treatment of cancer – nfP2X7.
nfP2X7 is a highly specific cancer target. Its non-reactivity with normal tissues along with the breadth of its presence in cancer, promises disruptive potential in the field of immunotherapy oncology.
The target nfP2X7 is unique:
it is highly specific to cancer cells (we have strong evidence indicating no cross reactivity in human)
it occurs across a broad range of cancers (nfP2X7 has been detected in +20 human tumor samples)
it constitutes a significant IP asset (Biosceptre has been awarded over 100 patents globally)
Biosceptre has multiple programs in the pipeline that exploit this new nfP2X7 oncology target via a range of modalities. Each has the potential to be a blockbuster in the treatment of cancer either individually or in combination with other treatments.
Biosceptres’ IP portfolio and expertise around the unique biology of the nfP2X7 target also promises significant potential for application & licensing across advanced therapeutic technologies, diagnostic and veterinarian uses.
Contact us to explore these opportunities at email@example.com